Psychopharmacology

, Volume 142, Issue 4, pp 393–398

Lorazepam for chronic catatonia: a randomized, double-blind, placebo-controlled cross-over study

Authors

  • G. S. Ungvari
    • Department of Psychiatry, The Chinese University of Hong Kong, Hong Kong, SAR, China
  • Helen F. K. Chiu
    • Department of Psychiatry, The Chinese University of Hong Kong, Hong Kong, SAR, China
  • Lok Yee Chow
    • Department of Psychiatry, The Chinese University of Hong Kong, Hong Kong, SAR, China
  • Benjamin S. T. Lau
    • Lai Chi Kok Hospital, Hong Kong, SAR, China
  • Wai Kwong Tang
    • Department of Psychiatry, The Chinese University of Hong Kong, Hong Kong, SAR, China
ORIGINAL INVESTIGATION

DOI: 10.1007/s002130050904

Cite this article as:
Ungvari, G., Chiu, H., Chow, L. et al. Psychopharmacology (1999) 142: 393. doi:10.1007/s002130050904

Abstract

Acute catatonic syndromes occurring in the context of various medical and neuropsychiatric conditions, including schizophrenia, have been shown to respond well to benzodiazepines (BZD). However, there have been no studies specifically designed to address the BZD treatment response of persistent catatonic states. Eighteen patients with clinically stable chronic schizophrenia, who also displayed enduring catatonic features, underwent a 12-week long, random assignment, double-blind, placebo-controlled cross-over trial with lorazepam (6 mg/day). A comprehensive assessment, including the subjects’ clinical and motor (catatonic as well as drug-induced movement disorders) condition, was performed at baseline and four weekly intervals thereafter. Pre-existing medication was kept constant throughout the study. Lorazepam had no effect on the subjects’catatonic signs and symptoms, suggesting that acute and chronic catatonic syndromes associated with schizophrenic illness might have a different neurobiological basis.

Key words CatatoniaSchizophreniaBenzodiazepine

Copyright information

© Springer-Verlag Berlin Heidelberg 1999